NCBiotech News

A new study conducted by researchers from Duke University, MIT and Singapore’s Nanyang Technological University shows that sound waves are capable of rapidly and efficiently separating circulating tumor cells (CTCs) from blood.

Even the best scientific innovation can be flattened by public distrust. That was the major reminder from Kevin Folta, Ph.D., a professor of horticultural sciences at the University of Florida, to dozens of people gathered at the North Carolina Biotechnology Center Wednesday. 

Professionals involved in the field of precision health have until September 14 to use a special discount code when registering to attend the September 24 and 25 Precision Medicine World Conference 2018 (PMWC) at Duke University’s Fuqua School of Business.

Burlington-based LabCorp has received approval from the U.S. Food and Drug Administration to market a diagnostic test that can detect four viruses in donated blood plasma used in making biologic therapies.

A British company with U.S. headquarters in Research Triangle Park has become the first to receive U.S. Food and Drug Administration approval for a prescription drug derived from marijuana.

Durham-based genome editing company Precision BioSciences announced that it has raised $110 million to further the development of its proprietary ARCUS genome editing platform.

Istari Oncology, a young Research Triangle Park biotechnology company started by a world-famous Duke University brain cancer team, has reported rare positive results in a Phase 1 clinical trial of its experimental treatment for glioblastoma.

North Carolina’s global precision health and gene therapy profile got a boost this week with the announcement that Swiss drug giant Roche will add $2.4 billion to the $1 billion it already invested, to buy gene testing company Foundation Medicine.

Startups, small businesses and incubators developing solutions for health security needs are invited to a U.S. Department of Health and Human Services pre-proposal Webex conference call on Friday, June 22, at First Flight Venture Center in Research Triangle Park. 

Glenmark Pharmaceuticals, an India-based global pharmaceutical company, has received its first U.S. Food and Drug Administration go-ahead to market one of its North Carolina-made drugs in the United States.

Durham-based Alcami has donated $15,000 to the Wilmington Fire Department to help fund IvyGene cancer screenings for firefighters, who face above-average risk of developing cancer.

​​​​​​​Chiesi USA of Cary and its European partner Holostem Terapie Avanzate have received Orphan Drug Designation from the U.S. Food and Drug Administration for an investigational cell-based therapy for a rare eye disease.

Small North Carolina technology firms, innovators, scientists and researchers will have the opportunity on June 21 and 22 to learn more about the U.S. Small Business Administration’s grant programs.

Moise Khayrallah, Ph.D., is a serial entrepreneur with a Midas touch. His latest startup, Durham-based Emergo Therapeutics, could be another golden opportunity after raising $12 million in venture capital this spring, mostly from North Carolina investors.

Morrisville-based Humacyte, developer of a bioengineered blood vessel, has formed a global partnership with Fresenius Medical Care, the world's largest provider of dialysis products and services, and will receive a $150 million equity investment as part of the deal.